Status:
WITHDRAWN
Exhaled Carbon Monoxide as a Marker of Hemolysis in Sickle Cell Disease- an Exploratory Study
Lead Sponsor:
University Hospitals Cleveland Medical Center
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
18+ years
Brief Summary
The investigators propose to evaluate etCO in patients with HbSS, HbSC, and HbS-beta thalassemia during routine clinic visits, and longitudinally. Our goal is to know whether etCO differs amongst subj...
Detailed Description
This is an observational study of sickle cell patients with the aim to measure exhaled carbon monoxide levels and to correlate with genotype and standard clinical markers of hemolysis. Upon enrollmen...
Eligibility Criteria
Inclusion
- All adult sickle patients presenting for follow up at the outpatient sickle cell clinic who are capable of following simple instructions.
Exclusion
- A recent (2 week) history of lung infection, asthma, acute chest syndrome, or COPD exacerbation and/or a significant pulmonary dysfunction in the recent (3-6 month) past.
Key Trial Info
Start Date :
June 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01888614
Start Date
June 1 2013
End Date
December 1 2016
Last Update
December 23 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seidman Cancer Center, University Hospitals
Cleveland, Ohio, United States, 44106